327 related articles for article (PubMed ID: 26028398)
21. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
22. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
24. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
Game F
Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
[TBL] [Abstract][Full Text] [Related]
25. A Sensitivity Analysis to Assess Bias Due to Selecting Subjects Based on Treatment Received.
Ertefaie A; Small D; Flory J; Hennessy S
Epidemiology; 2016 Mar; 27(2):e5-7. PubMed ID: 26628427
[No Abstract] [Full Text] [Related]
26. [New medications for patients with type 2 diabetes].
Meillet L
Soins; 2014 Oct; (789):15-8. PubMed ID: 25518129
[TBL] [Abstract][Full Text] [Related]
27. [Combination therapy with biguanides].
Sakura H
Nihon Rinsho; 2002 Oct; 60 Suppl 10():724-8. PubMed ID: 12430309
[No Abstract] [Full Text] [Related]
28. [Antidiabetic Drugs and the Kidney].
Candido R
G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
[No Abstract] [Full Text] [Related]
29. Diabetes under control: Understanding oral antidiabetic agents.
Longo R
Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
[No Abstract] [Full Text] [Related]
30. Pharmacological treatment of type 2 diabetes.
Hermans MP; Buysschaert M
Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
[No Abstract] [Full Text] [Related]
31. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
[TBL] [Abstract][Full Text] [Related]
32. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
34. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
Tahrani AA; Barnett AH; Bailey CJ
Nat Rev Endocrinol; 2016 Oct; 12(10):566-92. PubMed ID: 27339889
[TBL] [Abstract][Full Text] [Related]
35. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
36. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
Nauck MA
Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
[No Abstract] [Full Text] [Related]
37. What to add in with metformin in type 2 diabetes?
Petrie JR; Adler A; Vella S
QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
[TBL] [Abstract][Full Text] [Related]
38. [Drug treatment of type 2 diabetes].
Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
[TBL] [Abstract][Full Text] [Related]
39. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
[TBL] [Abstract][Full Text] [Related]
40. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]